
MVI: Innovating prostate cancer treatment with two unique DNA plasmid vaccines.
Madison Vaccines Incorporated (MVI) is dedicated to innovating prostate cancer treatment through the development of two unique DNA plasmid vaccines. Their core mission is to create intelligent clinical designs that realize the promise of immune-based therapies, specifically targeting prostate cancer. MVI focuses on providing innovative combination therapies that help men combat prostate cancer by changing the trajectory of PSA levels and delaying disease progression.
MVI has made significant strides in the field of immunotherapy, developing safe and effective treatments for patients at all stages of prostate cancer. Their work has had a meaningful impact on both patients and clinicians by offering new therapeutic options that improve patient outcomes. The company is recognized for its advanced approach to immune stimulants and its commitment to enhancing the quality of life for those affected by prostate cancer.

MimiVax
mimivax.com

Ubivac
ubivac.com

Irazu Oncology
irazuoncology.com

EpiVax Oncology
epivaxtx.com

Imvax
imvax.com

CellVax Therapeutics
cellvx.com

PepVax
pepvax.co

Agilvax

Cancervax
cancervax.com

Immunomic Therapeutics
immunomix.com

Vaccinex
vaccinex.com

NeuImmune
neuimmune.com

Immunophotonics

X-Vax Technology

Adventris Pharmaceuticals
Companies similar to Madison Vaccines include MimiVax, Ubivac, Irazu Oncology and EpiVax Oncology.
Madison Vaccines was founded in 2012.
Madison Vaccines' headquarters is located in Madison, WI, US.
Madison Vaccines' most recent funding round was for $3.3M (USD) in January 2017.
As of Jan 1, 2017, Madison Vaccines has raised a total of $15.8M (USD).
Madison Vaccines has 9 employees as of Feb 5, 2024.